BORAY — Bora Pharmaceuticals Co., Ltd./ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 2097461 ·
Last close
$2.59
Market Cap
$329.91M
52W High
$2.95
52W Low
$2.21
ADV30
2,505
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,860,654,000 | 1,772,261,000 | 557,571,000 | 331,759,000 | 44,714,187,000 | 5,076,889,000 | 27,241,998,000 |
| Sep 2025 | 4,806,145,000 | 2,171,873,000 | 1,063,577,000 | 633,610,000 | 43,741,050,000 | 4,409,046,000 | 28,052,540,000 |
| Jun 2025 | 4,867,785,000 | 2,019,383,000 | 992,758,000 | 616,669,000 | 41,963,962,000 | 4,309,662,000 | 27,895,803,000 |
| Mar 2025 | 4,479,585,000 | 1,889,497,000 | 681,383,000 | 1,399,273,000 | 46,758,653,000 | 5,125,635,000 | 31,603,635,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,503,589,000
Investing CF
$-3,379,649,000
Financing CF
$-1,376,910,000
CapEx
$-1,006,946,000
Dividends Paid
$0
Buybacks
$-76,207,000
EPS Diluted TTM
—
As of
2026-07-09
Balance + Analyst (yfinance extras)
Retained Earnings
$7,326,361,000
Inventory
$3,410,446,000
Receivables
—
ST Investments
$59,921,000
EBIT TTM
$5,762,510,000
Pretax Income TTM
$5,277,888,000
Interest Exp TTM
$484,622,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,535,815,168
EBITDA
$3,918,189,056
Free Cash Flow
$1,363,539,584
Enterprise Value
$16,368,283,648
Total Cash
$4,887,644,160
Total Debt
$17,546,782,720
Shares Out
127,379,859
Trailing EPS
—
Book Value
$0.71
ROE
11.0%
ROA
4.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 19,014,169,000 | 3,295,289,000 | 2,981,311,000 | 44,714,187,000 | 27,241,998,000 | — | 4,503,589,000 |
| Dec 2024 | 17,426,624,000 | 3,708,000,000 | 3,852,515,000 | 45,509,645,000 | 30,586,316,000 | — | 980,024,000 |
| Dec 2023 | 14,200,068,000 | 5,249,139,000 | 3,030,142,000 | 25,134,173,000 | 13,368,362,000 | — | 4,613,657,000 |
| Dec 2022 | 10,494,470,000 | 1,922,176,000 | 1,391,916,000 | 22,761,215,000 | 17,620,759,000 | — | 2,010,074,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RMR | RMR GROUP INC. | $329.75M | $20.49 | — |
| MSB | MESABI TRUST | $329.31M | $25.10 | — |
| PPT | PUTNAM PREMIER INCOME TRUST | $328.75M | $3.44 | — |
| RFMZ | RiverNorth Flexible Municipal Income Fund II, Inc. | $331.43M | $13.61 | — |
| MASS | 908 Devices Inc. | $332.32M | $8.10 | — |
News headlines (Yahoo Finance, 1h cache)
Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations
2026-07-02 15:00 · Yahoo
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
2026-07-02 13:25 · Yahoo
UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)
2026-05-20 14:00 · Yahoo
GMP Manufacturing Sale Gives MacroGenics Additional Non-Dilutive Capital for Pipeline Development (MGNX)
2026-05-12 15:08 · Yahoo
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
2026-05-11 21:20 · Yahoo
UPSHER-SMITH LAUNCHES NEW ONLINE RESOURCES TO SUPPORT THE DUCHENNE COMMUNITY
2026-04-14 14:00 · Yahoo
UPSHER-SMITH LAUNCHES GENERIC VERSION OF CIPRODEX® (CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1%) STERILE OTIC SUSPENSION
2026-04-06 18:01 · Yahoo
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
2026-03-13 12:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
2026-03-10 14:21 · Yahoo
Bora Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12th
2026-03-03 13:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.